Fugitive Acromegaly: A Historical, Clinical, and Translational Perspective
Frontiers of Hormone Research · 2024
DOI: 10.1159/000539942 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers of Hormone Research, 2024. Verfasst von Roberto Toni und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Tufts Medical Center - Tufts University School of Medicine, Boston, Mass…. Hauptthemen laut MEDLINE: Acromegaly. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
The term 'fugitive acromegaly' was introduced by the neurosurgeons Bailey and Cushing in 1928 to describe subjects manifesting signs and symptoms of somatotroph hyperfunction with pituitary insufficiency. Currently, it identifies patients with subtle acromegalic dysmorphisms and inconsistent hormonal profile, possibly presenting only with hyperprolactinemia and related clinical symptoms. Patients have rapidly growing, locally invasive, relapsing pituitary macrotumors that can be classified as either acidophil stem cell tumors (ASCTs) or sparsely granulated somatotroph tumors (SGSTs), both of PIT1-lineage. ASCTs also express estrogen receptor (ER)α, show predominant prolactin (PRL) release, and less abundantly, growth hormone (GH). In contrast, SGSTs have moderately increased GH and IGF1 levels, but rarely PRL increase. ASCTs often present resistance to dopamine agonists, and long-acting somatostatin analogs are used. In contrast, SGSTs are often resistant to somatostatin analogues and instead are treated with the GH receptor antagonist pegvisomant. Differential diagnosis includes mammosomatotroph, mixed GH-/PRL-secreting, immature PIT1-lineage, and densely granulated somatotroph tumors. Studies in ER-sensitive rat tumoral mammosomatotroph cells (GH3, GH4C1) suggest that overexpression of chaperones in immature PIT1-/ER-expressing progenitors induces posttranscriptional conformational changes to tumor suppressors of the ERα and aryl hydrocarbon receptor pathways, like AIP, leading to the development of aggressive pituitary tumors like those causing fugitive acromegaly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Tufts Medical Center - Tufts University School of Medicine, Boston, Massachusetts, USA.
- Institute of Science and Development of Ceramic Materials (ISSMC), CNR, Faenza, Italy.
- Academy of Sciences of the Institute of Bologna, Section IV - Medical Sciences, Bologna, Italy.
- Endocrinology, Diabetes, and Nutrition Disorders Outpatient Clinic - Osteoporosis, Nutrition, Endocrinology, and Innovative Therapies (OSTEONET) Unit, Galliera Medical Center, San Venanzio di Galliera, Italy.
- Department of Medicine and Surgery (DIMEC), Unit of Biomedical, Biotechnological and Translational Sciences (S.BI.BI.T.), Laboratory of Regenerative Morphology and Bioartificial Structures (Re.Mo.Bio.S.), and Museum and…
- Food and Drug Department, University of Parma, Parma, Italy.
Zitieren
APA
Toni, R., Barbaro, F., Di Conza, G., Elviri, L., Mosca, S., Caravelli, S., Mosca, M., Arkun, K., Asa, S. L., & Lechan, R. M. (2024). Fugitive Acromegaly: A Historical, Clinical, and Translational Perspective. Frontiers of Hormone Research. https://doi.org/10.1159/000539942
Vancouver
Toni R, Barbaro F, Di Conza G, Elviri L, Mosca S, Caravelli S, et al. Fugitive Acromegaly: A Historical, Clinical, and Translational Perspective. Frontiers of Hormone Research. 2024. doi:10.1159/000539942
BibTeX
@article{Toni2024,
author = {Toni, Roberto and Barbaro, Fulvio and Di Conza, Giusy and Elviri, Lisa and Mosca, Salvatore and Caravelli, Silvio and Mosca, Massimiliano and Arkun, Knarik and Asa, Sylvia L and Lechan, Ronald M},
title = {Fugitive Acromegaly: A Historical, Clinical, and Translational Perspective},
journal = {Frontiers of Hormone Research},
year = {2024},
doi = {10.1159/000539942}
}
EUVIMED